The third-most potent hit was trans-ISRIB (Fig. 2C), a known PR acting through inhibition of the PERK-mediated UPR pathway, whereby it releases the brake on translation (73); its potential therapeutic utility for GD or GBA1-PD remains to be determined. Here, PAEP is linked to Parkinson disease.